Minaris Regenerative Medicine, a global contract development and manufacturing organization for cell and gene therapies, is investing $64.5 million to significantly expand its facilities in Europe and Asia. A new state-of-the-art facility will be built near its existing site in Ottobrunn near Munich, Germany with a total investment of $40.7 million. The new facility will operate according to GMP standards (FDA and EMA) and be dedicated to clinical and commercial manufacturing as well as deve...